Methotrexate (MTX) has been established as a standard disease-modifying anti-rheumatic drug. If adequate disease control is achieved for a reasonable period of time, tapering the MTX dosage is recommended because the chronic use of MTX can result in opportunistic infection. We present here a case of a woman with rheumatoid arthritis taking MTX, and the woman developed actively caseating endobronchial 

Mycobacterium intracellulare disease with pulmonary infiltrations. After discontinuing the MTX, the patient was able to tolerate 18 months of antitycobacterial treatment without flare ups of rheumatoid arthritis, and she completely recovered from nontuberculous mycobacterial respiratory disease.

Keywords: Nontuberculous Mycobacteria; Tuberculosis, Pulmonary; Methotrexate; Arthritis, Rheumatoid; Bronchial Diseases

**Introduction**

During the past decades, methotrexate (MTX) was regarded as a disease-modifying anti-rheumatic drug due to its effectiveness and safety profile for the treatment of rheumatoid arthritis (RA). MTX has been established as the standard disease-modifying anti-rheumatic drug for the treatment of RA. Infections are common in patients with RA and this may be related either to the underlying RA or to the use of the immunosuppressive drugs, such as MTX. Nontuberculous mycobacteria (NTM) are ubiquitous bacteria and they have been increasingly detected in both immunocompromised and immunocompetent hosts. NTM infection may result in an endobronchial infection that is similar to an ordinary tuberculous infection. Although several cases of the endobronchial lesions caused by NTM infection have been reported, to the best of our knowledge, an actively caseating endobronchial infection has not been reported in a non-human immunodeficiency virus patient.

We present here an unusual case of actively caseating endobronchial 

Mycobacterium intracellulare disease in a patient with RA and who developed this infection while receiving MTX.
Case Report

A 58-year-old woman was admitted to our hospital with a two-month history of a worsening productive cough, fatigue, and fever. The patient had a 20-year history of RA involving primarily her hands and wrists, and her disease had become refractory to multiple non-steroidal anti-inflammatory drugs over the past several years. Three years ago, the patient had commenced treatment with MTX at a dose of 12.5 mg per week with concomitant acetaminophen 650 mg twice daily. She had achieved control with these medications. She has never had a similar respiratory problem before. She also complained of mild chest pain, shortness of breath, night sweats and anorexia. The shortness of breath was progressive in nature and it was aggravated by strenuous activities and it subsided when taking a rest.

On physical examination, the patient appeared chronically ill. She was appropriately alert and oriented. She has a body temperature of 37.8°C and regular heart rhythm with a rate of 80 beats/min. Her blood pressure was 140/80 mm Hg and the respiratory rate was 25 breaths/min. The respiratory system examination was entirely normal except for bibasilar crackles noted on auscultation.

At the time of presentation a complete blood cell count showed a hemoglobin level of 10.9 g/dL and a white blood cell of 6,380 cells/mm³ with 74% neutrophils, and 20% lymphocytes. The other laboratory results were as follows: the erythrocyte sedimentation rate was 28 mm/hr, the C-reactive protein was 6.33 mg/dL, the RA factor was 27.7 IU/mL, and the anti nuclear antibody, the anti-neutrophil cytoplasmic antibodies and the anti-ds-DNA were all negative. The anti-human immunodeficiency virus (HIV) antibody was also negative. A chest X-ray revealed multifocal nodular consolidation and ill-defined nodules in both lungs, and this was more prominent in the mid-lung field of the right lung and there was no evidence of mediastinal lymphadenopathy (Figure 1).

Figure 1. Plain radiography (A) and computed tomography (B) of the chest of a 58-year-old woman who was infected with Mycobacterium intracellulare showed multifocal nodular consolidation and ill-defined nodules in both lungs, and this was all more prominent in the mid-lung field of the right lung, without evidence of mediastinal lymphadenopathy.

Figure 2. Bronchoscopic photograph of the left main (A) revealed diffuse actively caseating endobronchial lesions. The bronchial biopsy specimen (B) from the left main bronchi showed granulomatous inflammation with caseating necrosis (H&E stain, ×100).
Bronchoscopy at this time revealed diffuse actively caseating endobronchial lesions in the left main and left upper lobar bronchus (Figure 2). The bronchial biopsy specimen from the left main bronchus showed granulomatous inflammation with caseating necrosis (Figure 2). Ziehl-Neelsen staining of the bronchial washing fluid and expectorated sputum showed acid-fast bacilli (AFB). The polymerase chain reaction test for the specific sequences of *M. tuberculosis* was negative.

The MTX was discontinued. Her RA was treated with hydroxychloroquine sulfate 100 mg twice daily, nambumetone 500 mg twice daily and acetaminophen 650 mg twice daily. She was empirically treated with isonizid (300 mg/day), rifampin (600 mg/day), ethambutol (800 mg/day), and pyrazinamide (1,500 mg/day) for tuberculosis pending the AFB culture results. Subsequently, the fever and cough subsided, and the fatigue and shortness of breath regressed. After 6 weeks, the mycobacterium culture of the sputum and bronchial washing fluid yielded *M. intracellulare*. The isonizid and pyrazinamide were discontinued. Antimycobacterial therapy was continued with rifampin, ethambutol, and clarithromycin (500 mg twice daily) for 18 months with a good response. Follow up bronchoscopy after 2 months of therapy revealed that the actively caseating endobronchial lesion had completely resolved. At the return visits 3 and 6 months later, the patient was able to do most of her daily activities without respiratory symptoms, and she well tolerated the antimycobacterial medications without any adverse reactions. The chest X-ray checked at the end of the treatment showed normal findings.

At eight months after completing the antimycobacterial medications, the patient was still totally free of respiratory symptoms and the sputum culture for AFB was negative.

**Discussion**

In this report we have described actively caseating endobronchial NTM disease in a patient with RA and who developed infection while receiving MTX. The patient was found to have actively caseating endobronchial lesions and a pulmonary infiltration due to *M. intracellulare*. Pulmonary infection caused by *M. intracellulare* is common in immunocompromised patients such as HIV-infected patients. Although the specific immunologic dysfunction that predisposes patients to NTM infection is unknown, although defects in interleukin-12 and interferon-γ production are known to increase the risk for disseminated NTM disease in humans. An exact epidemiologic study on NTM disease has not been reported. However, the recent data has suggested that the prevalence of NTM disease is increasing. Especially, the popular use of biologic, immune-suppressive therapies for treating patients with RA and other autoimmune inflammatory disease might be associated with NTM pulmonary infections.

Our patient had a clinical picture of fever, dyspnea, cough and night sweats, and her actively caseating endobronchial lesions were different from the obstructive endobronchial lesions of the previously reported cases. The consolidation and nodular shadows were more prominently observed in right-side lung than in left-side lung, but actively caseating lesions were found in left main and left upper lobe bronchus. Endobronchial tuberculosis has been combined in 10% to 20% of patients with active parenchymal disease. It can be caused by spread of tubercle bacilli within the airway lumen or along peribronchial lymphatic channels from an area of cavitations or tuberculous pneumonia. Left-side airways are more commonly involved than right-side airways because they are anatomically compressed by the aortic arch, and the left main bronchus is vulnerable to pathologic stricture. Taken together, these previous reports could explain the reason why the prominent side of pulmonary lesions were different from that of endobronchial lesions in our patient.

Endobronchial lesions caused by NTM infection have already been reported in several studies. The majorities of these patients were HIV-infected and they presented with polypoid masses that caused obstruction of their airways. These lesions responded to antimycobacterial therapy and resection using biopsy forceps.

In one retrospective study on *Pneumocystis jiroveci* pneumonia, the number of RA patients with fatal outcome from this infection was higher when they had been treated with MTX as compared to those patients who were not treated with MTX.

Weekly low doses of oral MTX treatment have become the therapy of choice for patients with RA. There are several reasons for its wide acceptance, including the good disease control, the convenient dosing and the low toxicity compared with other options for antirheumatic therapy. However, despite its wide use along with the increased risk of infection, the previous studies have shown a significant disparity in the prescribing patterns of MTX among physicians. If adequate disease control is achieved for a reasonable period of time, tapering the MTX dosage is recommended because this therapy is not innocuous, and some unwanted drug adverse reactions may arise from the chronic usage of MTX. Because the chronic use of MTX can result in immunologic impairment, doctors who manage patients with this drug should pay attention about the increased risk of opportunistic infection. So, dose reduction or extending the interval for MTX therapy may be a valid therapeutic method after clinical remission, such as in this current patient. For the current patient, the doses and the interval for MTX had not changed for 3 years. We think that these conditions might have predisposed our patient to NTM infection. Actually, after discontinuing the MTX, the patient was able to tolerate 18 months of antimycobacterial treatment without flare ups of RA, and she completely recovered from the NTM respiratory disease. In summary, we report here on an unusual case of actively
Actively caseating endobronchial NTM disease

caseating endobronchial *M. intracellulare* disease with a pulmonary infiltration in a patient with RA, and the patient developed this infection while receiving MTX. According to our findings, NTM infection should be considered in RA patients with chronic usage of the immunosuppressive drugs, such as MTX, especially in proper clinical setting, and prompt diagnosis is important for the effective treatment and prevention of a bronchial stricture.

**References**

1. Aletaha D, Smolen JS. The rheumatoid arthritis patient in the clinic: comparing more than 1,300 consecutive DMARD courses. Rheumatology (Oxford) 2002;41:1367-74.

2. Pincus T, Yazici Y, Sokka T, Aletaha D, Smolen JS. Methotrexate as the “anchor drug” for the treatment of early rheumatoid arthritis. Clin Exp Rheumatol 2003;21(5 Suppl 31):S179-85.

3. Koh WJ, Kwon OJ, Jeon K, Kim TS, Lee KS, Park YK, et al. Clinical significance of nontuberculous mycobacteria isolated from respiratory specimens in Korea. Chest 2006;129:341-8.

4. Griffith DE, Aksamit T, Brown-Elliott BA, Catanzaro A, Daley C, Gordin F, et al. An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med 2007;175:367-416.

5. Shih JY, Wang HC, Chiang IP, Yang PC, Luh KT. Endobronchial lesions in a non-AIDS patient with disseminated *Mycobacterium avium-intracellulare* infection. Eur Respir J 1997;10:497-9.

6. Mehle ME, Adamo JP, Mehta AC, Wiedemann HP, Keys T, Longworth DL. Endobronchial *Mycobacterium avium-intracellulare* infection in a patient with AIDS. Chest 1989;96:199-201.

7. Lee JH, Son KS, Park JH, Kim JC, Lee HW, Kim CH. *Mycobacterium avium* infection presenting as endobronchial lesions in an immunocompetent patient. Tuberc Respir Dis 2006;60:571-5.

8. O’Brien RJ, Geiter LJ, Snider DE Jr. The epidemiology of nontuberculous mycobacterial diseases in the United States: results from a national survey. Am Rev Respir Dis 1987;135:1007-14.

9. Rosenzweig SD, Holland SM. Defects in the interferon-gamma and interleukin-12 pathways. Immunol Rev 2005;203:38-47.

10. Kolokotronis A, Avramidou E, Zaraboukas T, Mandraveli K, Alexiou S, Antoniades D. Oral tuberculosis associated with a treatment with anti-rheumatic drugs. J Oral Pathol Med 2006;35:123-5.

11. Lee JY, Yi CA, Kim TS, Kim H, Kim J, Han J, et al. CT scan features as predictors of patient outcome after bronchial intervention in endobronchial TB. Chest 2010;138:380-5.

12. Watanabe Y, Murakami S, Iwa T. Bronchial stricture due to endobronchial tuberculosis. Thorac Cardiovasc Surg 1988;36:27-32.

13. Iikuni N, Kitahama M, Ohta S, Okamoto H, Kamatani N, Nishinarita M. Evaluation of *Pneumocystis pneumonia* infection risk factors in patients with connective tissue disease. Mod Rheumatol 2006;16:282-8.

14. Luis M, Pacheco-Tena C, Cazarin-Barrientos J, Lino-Perez L, Goycochea MV, Vazquez-Mellado J, et al. Comparison of two schedules for administering oral low-dose methotrexate (weekly versus every-other-week) in patients with rheumatoid arthritis in remission: a twenty-four week, single blind, randomized study. Arthritis Rheum 1999;42:2160-5.

15. Visser K, Katchamart W, Loza E, Martinez-Lopez JA, Salliot C, Trudeau J, et al. Multinational evidence-based recommendations for the use of methotrexate in rheumatic disorders with a focus on rheumatoid arthritis: integrating systematic literature research and expert opinion of a broad international panel of rheumatologists in the 3E Initiative. Ann Rheum Dis 2009;68:1086-93.